ES2264886B1 - Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. - Google Patents
Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. Download PDFInfo
- Publication number
- ES2264886B1 ES2264886B1 ES200501141A ES200501141A ES2264886B1 ES 2264886 B1 ES2264886 B1 ES 2264886B1 ES 200501141 A ES200501141 A ES 200501141A ES 200501141 A ES200501141 A ES 200501141A ES 2264886 B1 ES2264886 B1 ES 2264886B1
- Authority
- ES
- Spain
- Prior art keywords
- oil
- use according
- dha
- weight
- docosahexaenoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title claims abstract description 137
- 235000020669 docosahexaenoic acid Nutrition 0.000 title claims abstract description 69
- 229940090949 docosahexaenoic acid Drugs 0.000 title claims abstract description 68
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 25
- 229930195729 fatty acid Natural products 0.000 claims abstract description 25
- 239000000194 fatty acid Substances 0.000 claims abstract description 25
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 12
- 125000005456 glyceride group Chemical group 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 42
- 230000000694 effects Effects 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 17
- 239000000203 mixture Substances 0.000 description 13
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 11
- 239000004530 micro-emulsion Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 239000006014 omega-3 oil Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 150000002066 eicosanoids Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical class N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- NBWRJAOOMGASJP-UHFFFAOYSA-N 2-(3,5-diphenyl-1h-tetrazol-1-ium-2-yl)-4,5-dimethyl-1,3-thiazole;bromide Chemical compound [Br-].S1C(C)=C(C)N=C1N1N(C=2C=CC=CC=2)N=C(C=2C=CC=CC=2)[NH2+]1 NBWRJAOOMGASJP-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501141A ES2264886B1 (es) | 2005-05-12 | 2005-05-12 | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
| PCT/EP2006/061833 WO2006120120A1 (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic glycerides for the treatment of tumorous diseases |
| JP2008510532A JP5893235B2 (ja) | 2005-05-12 | 2006-04-26 | 腫瘍性疾患の治療のためのドコサヘキサエン酸グリセリドの使用 |
| NZ563301A NZ563301A (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic glycerides for the treatment of tumoral diseases |
| DK06754856.0T DK1881824T3 (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic acid triglycerides for the treatment of tumor diseases |
| US11/913,994 US20080207947A1 (en) | 2005-05-12 | 2006-04-26 | Use Of Docosahexaenoic Glycerides For The Treatment Of Tumorous Diseases |
| HK08108365.2A HK1113319B (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic triglycerides for the treatment of tumorous diseases |
| ES06754856.0T ES2531599T3 (es) | 2005-05-12 | 2006-04-26 | Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales |
| PL06754856T PL1881824T3 (pl) | 2005-05-12 | 2006-04-26 | Zastosowanie triglicerydów kwasu dokozaheksaenowego w leczeniu chorób nowotworowych |
| CA2614192A CA2614192C (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic glycerides for the treatment of tumoral diseases |
| PT06754856T PT1881824E (pt) | 2005-05-12 | 2006-04-26 | Utilização de triglicéridos docosaexaenóicos para o tratamento de doenças tumorais |
| EP06754856.0A EP1881824B1 (en) | 2005-05-12 | 2006-04-26 | Use of docosahexaenoic triglycerides for the treatment of tumorous diseases |
| IL187274A IL187274A (en) | 2005-05-12 | 2007-11-08 | Use of docosahexaenoic glycerides for the preparation of medicaments for the treatment of tumoral diseases |
| NO20076382A NO336953B1 (no) | 2005-05-12 | 2007-12-11 | Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer |
| US12/550,780 US9271954B2 (en) | 2005-05-12 | 2009-08-31 | Use of docosahexaenoic glycerides for the treatment of tumorous diseases |
| JP2014128247A JP6038841B2 (ja) | 2005-05-12 | 2014-06-23 | 腫瘍性疾患の治療のためのドコサヘキサエン酸グリセリドの使用 |
| US15/005,181 US20170333381A9 (en) | 2005-05-12 | 2016-01-25 | Use of Docosahexaenoic Glycerides For The Treatment Of Tumorous Diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200501141A ES2264886B1 (es) | 2005-05-12 | 2005-05-12 | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2264886A1 ES2264886A1 (es) | 2007-01-16 |
| ES2264886B1 true ES2264886B1 (es) | 2008-02-01 |
Family
ID=36809521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200501141A Expired - Lifetime ES2264886B1 (es) | 2005-05-12 | 2005-05-12 | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
| ES06754856.0T Expired - Lifetime ES2531599T3 (es) | 2005-05-12 | 2006-04-26 | Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06754856.0T Expired - Lifetime ES2531599T3 (es) | 2005-05-12 | 2006-04-26 | Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080207947A1 (https=) |
| EP (1) | EP1881824B1 (https=) |
| JP (2) | JP5893235B2 (https=) |
| CA (1) | CA2614192C (https=) |
| DK (1) | DK1881824T3 (https=) |
| ES (2) | ES2264886B1 (https=) |
| IL (1) | IL187274A (https=) |
| NO (1) | NO336953B1 (https=) |
| NZ (1) | NZ563301A (https=) |
| PL (1) | PL1881824T3 (https=) |
| PT (1) | PT1881824E (https=) |
| WO (1) | WO2006120120A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2264886B1 (es) * | 2005-05-12 | 2008-02-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
| BRPI0613358A8 (pt) * | 2005-07-08 | 2017-12-26 | Dsm Ip Assets Bv | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência |
| EP1962825B1 (en) * | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| NZ586249A (en) * | 2007-12-19 | 2012-05-25 | Prometic Biosciences Inc | A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer |
| WO2011103514A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha triglyceride emulsions |
| US20110200644A1 (en) * | 2010-02-18 | 2011-08-18 | Martek Biosciences Corporation | DHA Ester Emulsions |
| WO2011103512A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha free fatty acid emulsions |
| KR101643259B1 (ko) * | 2010-07-26 | 2016-07-27 | 후지필름 가부시키가이샤 | 유지 함유 조성물 및 그것을 포함하는 경구제제 |
| MX370055B (es) | 2013-04-22 | 2019-11-29 | Smartfish As | Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer. |
| KR101665253B1 (ko) | 2015-06-19 | 2016-10-25 | 순천향대학교 산학협력단 | 도코사헥사에노산 및 트리아신 씨를 포함하는 것을 특징으로 하는 자궁내막암 치료 및 예방용 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0462398A1 (en) * | 1990-05-22 | 1991-12-27 | F. Hoffmann-La Roche Ag | TGF-beta compositions |
| WO2001017524A1 (en) * | 1999-09-09 | 2001-03-15 | Efa Sciences Llc. | Methods for treating cell proliferative disorders including cancer |
| US20040052837A1 (en) * | 2002-06-27 | 2004-03-18 | William Stillwell | Lipid conjugated anti-cancer drugs and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3721137A1 (de) * | 1987-06-26 | 1989-01-05 | Dietl Hans | Fettemulsion zur intravenoesen anwendung |
| JP2572692B2 (ja) * | 1991-07-24 | 1997-01-16 | ボーソー油脂 株式会社 | ドコサヘキサエン酸トリグリセリドの製造法 |
| JPH05139968A (ja) * | 1991-11-14 | 1993-06-08 | Sagami Chem Res Center | メダラシン活性促進剤 |
| JPH0616548A (ja) * | 1992-06-30 | 1994-01-25 | Sagami Chem Res Center | 組織異常増殖抑制剤 |
| JPH06116585A (ja) * | 1992-10-09 | 1994-04-26 | Kanegafuchi Chem Ind Co Ltd | 油脂の精製方法 |
| JP3526632B2 (ja) * | 1994-08-22 | 2004-05-17 | 旭化成ケミカルズ株式会社 | 高度不飽和脂肪酸含有油脂 |
| JPH1057086A (ja) * | 1996-08-20 | 1998-03-03 | Asahi Chem Ind Co Ltd | 高濃度ドコサヘキサエン酸モノグリセリドの製造方法 |
| JP2002180082A (ja) * | 2000-12-11 | 2002-06-26 | Maruha Corp | 摂取物 |
| ES2264886B1 (es) * | 2005-05-12 | 2008-02-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
-
2005
- 2005-05-12 ES ES200501141A patent/ES2264886B1/es not_active Expired - Lifetime
-
2006
- 2006-04-26 US US11/913,994 patent/US20080207947A1/en not_active Abandoned
- 2006-04-26 WO PCT/EP2006/061833 patent/WO2006120120A1/en not_active Ceased
- 2006-04-26 EP EP06754856.0A patent/EP1881824B1/en not_active Expired - Lifetime
- 2006-04-26 ES ES06754856.0T patent/ES2531599T3/es not_active Expired - Lifetime
- 2006-04-26 PL PL06754856T patent/PL1881824T3/pl unknown
- 2006-04-26 CA CA2614192A patent/CA2614192C/en not_active Expired - Fee Related
- 2006-04-26 JP JP2008510532A patent/JP5893235B2/ja not_active Expired - Lifetime
- 2006-04-26 NZ NZ563301A patent/NZ563301A/en not_active IP Right Cessation
- 2006-04-26 DK DK06754856.0T patent/DK1881824T3/en active
- 2006-04-26 PT PT06754856T patent/PT1881824E/pt unknown
-
2007
- 2007-11-08 IL IL187274A patent/IL187274A/en active IP Right Grant
- 2007-12-11 NO NO20076382A patent/NO336953B1/no not_active IP Right Cessation
-
2009
- 2009-08-31 US US12/550,780 patent/US9271954B2/en not_active Expired - Lifetime
-
2014
- 2014-06-23 JP JP2014128247A patent/JP6038841B2/ja not_active Expired - Lifetime
-
2016
- 2016-01-25 US US15/005,181 patent/US20170333381A9/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0462398A1 (en) * | 1990-05-22 | 1991-12-27 | F. Hoffmann-La Roche Ag | TGF-beta compositions |
| WO2001017524A1 (en) * | 1999-09-09 | 2001-03-15 | Efa Sciences Llc. | Methods for treating cell proliferative disorders including cancer |
| US20040052837A1 (en) * | 2002-06-27 | 2004-03-18 | William Stillwell | Lipid conjugated anti-cancer drugs and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| IL187274A (en) | 2011-11-30 |
| US9271954B2 (en) | 2016-03-01 |
| US20170333381A9 (en) | 2017-11-23 |
| DK1881824T3 (en) | 2015-02-23 |
| US20090318553A1 (en) | 2009-12-24 |
| ES2264886A1 (es) | 2007-01-16 |
| WO2006120120A1 (en) | 2006-11-16 |
| EP1881824A1 (en) | 2008-01-30 |
| HK1113319A1 (en) | 2008-10-03 |
| NZ563301A (en) | 2010-08-27 |
| US20080207947A1 (en) | 2008-08-28 |
| IL187274A0 (en) | 2008-06-05 |
| CA2614192A1 (en) | 2006-11-16 |
| PL1881824T3 (pl) | 2015-06-30 |
| NO20076382L (no) | 2008-02-08 |
| JP5893235B2 (ja) | 2016-03-23 |
| CA2614192C (en) | 2014-03-18 |
| JP6038841B2 (ja) | 2016-12-07 |
| EP1881824B1 (en) | 2014-12-24 |
| JP2014208677A (ja) | 2014-11-06 |
| NO336953B1 (no) | 2015-11-30 |
| JP2008540484A (ja) | 2008-11-20 |
| ES2531599T3 (es) | 2015-03-17 |
| PT1881824E (pt) | 2015-03-26 |
| US20160193175A1 (en) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9271954B2 (en) | Use of docosahexaenoic glycerides for the treatment of tumorous diseases | |
| Long et al. | Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery | |
| Suntres | Role of antioxidants in paraquat toxicity | |
| US5925669A (en) | Carrier compositions for anti-neoplastic drugs | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| BR112012029170B1 (pt) | uso de um fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo | |
| MXPA01008245A (es) | Combinaciones para el tratamiento de las enfermedades que comprenden angiogenesis. | |
| Mohammad et al. | Vesicular drug delivery system used for liver diseases | |
| JP2012511510A (ja) | 薬物として使用するためのシス−一不飽和脂肪酸のα誘導体 | |
| Zhang et al. | Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies—Exemplified by polyunsaturated fatty acids and other ROS-modulating agents | |
| US20220249438A1 (en) | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | |
| KR101666969B1 (ko) | 레스베라트롤 및 타우린을 유효성분으로 포함하는 뇌신경질환 치료 및 신경세포 보호용 조성물 | |
| CN111542325A (zh) | 用于治疗恶性肿瘤和癌前病症的组合物及其使用方法和制备药剂的方法 | |
| JPS6277319A (ja) | がん転移抑制剤 | |
| Liu et al. | Research progress on pharmacological action and effective drug carrier of berberine. | |
| WO2006054316A1 (en) | Method(s) of preparation, stabilization, composition, and administration of gamma-linolenic acid for brain tumors | |
| HK1113319B (en) | Use of docosahexaenoic triglycerides for the treatment of tumorous diseases | |
| IL274203B1 (en) | A pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease | |
| JP2019131508A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| ES2442450B1 (es) | Liposomas vacíos como adyuvante de diferentes principios activos, administrados independientemente y en su forma galénica convencional | |
| Handali et al. | Mitochondria and cancer therapy | |
| ES2363394A1 (es) | Uso de amitriptilina como agente antitumoral para el tratamiento de cáncer de pulmón. | |
| KR20160036490A (ko) | 중쇄 지방산을 포함하는 암치료용 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20070116 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2264886B1 Country of ref document: ES |